Journal
JOURNAL OF THORACIC DISEASE
Volume 10, Issue -, Pages S304-S310Publisher
AME PUBL CO
DOI: 10.21037/jtd.2017.10.19
Keywords
Chemotherapy (CT); malignant pleural mesothelioma (MPM); pemetrexed; platinum
Categories
Ask authors/readers for more resources
Malignant pleural mesothelioma (MPM) is a rare neoplasm that typically arises from mesothelial surfaces of the pleural cavity. Despite treatment improvements, it carries a dismal prognosis. The majority of patients either have unresectable disease or are not candidates for surgery due to medical comorbidities or old age. For such patients, chemotherapy (CT) represents the gold-standard treatment. To date, combination CT with cisplatin plus pemetrexed represents the most widely used regimen in first-line setting for patients with unresectable MPM. Other first-line options are currently available, including the use of raltitrexed instead of pemetrexed combined with platinum. In this review, we discuss the role of CT in MPM mainly focusing on the results of the trials conducted in first-line setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available